The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GRRMF | -47.6% | -63.45% | -18.22% | +71% |
| S&P | +13.95% | +78.35% | +12.25% | +730% |
Gerresheimer AG manufactures and supplies glass and plastic products for the pharmaceutical and healthcare industry. It operates through the following segments: Plastic and Devices and Primary Packaging Glass. The Plastic and Devices segment includes insulin pens, inhalers and refillable syringes as well as diagnostics and medical technology products such as skin-prick aids and test systems and pharmaceutical plastic containers for liquid and solid medicines. The Primary Packaging Glass segment refers to the primary packaging made of glass of medicines and cosmetics such as pharma jars, ampoules, injection vials, cartridges, perfume flacons and cream jars, and special containers for food and drinks. The company was founded in 1864 and is headquartered in Duesseldorf, Germany.
No news articles found for Gerresheimer Ag.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $650.87M | 20.0% |
| Gross Profit | $161.24M | 0.3% |
| Gross Margin | 24.77% | -4.9% |
| Market Cap | $1.78B | -51.6% |
| Market Cap / Employee | $131.19K | -57.0% |
| Employees | 13.5K | 12.7% |
| Net Income | -$14,244.92K | -147.3% |
| EBITDA | $173.00M | 22.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $170.74M | 40.9% |
| Accounts Receivable | $340.78M | 9.2% |
| Inventory | 598.6 | 45.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.00B | 175.8% |
| Short Term Debt | $533.87M | -20.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 0.54% | -2.7% |
| Return On Invested Capital | 5.07% | -0.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $6.66M | 151.1% |
| Operating Free Cash Flow | $94.57M | 21.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 22.88 | 33.64 | 35.47 | 67.86 | 111.39% |
| Price to Book | 1.97 | 1.78 | 1.62 | 1.09 | -52.42% |
| Price to Sales | 1.23 | 1.29 | 1.05 | 0.70 | -61.36% |
| Price to Tangible Book Value | 13.64 | 9.97 | -9.08 | -5.19 | -135.49% |
| Enterprise Value to EBITDA | 29.77 | 57.11 | 37.29 | 23.89 | -35.94% |
| Return on Equity | 7.5% | 5.5% | 4.3% | 1.6% | -79.74% |
| Total Debt | $1.36B | $2.25B | $2.50B | $2.53B | 81.50% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
